Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis

Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal... EDITORIAL Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis EPHROGENIC SYSTEMIC FIBROSIS (NSF) IS fore the disease developed. In August, Marckmann et al an acquired condition that occurs in the described a series of 13 patients with end-stage renal dis- setting of chronic kidney disease (CKD), ease (7 who were receiving hemodialysis, 1 who was re- and it eventuates as fibrosis of the skin, ceiving peritoneal dialysis, and 5 who did not require di- N soft tissues, and sometimes the viscera. alysis) who developed NSF a mean of 25 days after For nearly a decade, the cause of NSF remained largely gadodiamide exposure. In November, my own research elusive. Only recently have the combined efforts of mul- group, using scanning electron microscopy with energy- tiple investigators shed light on key associations and pos- dispersive spectroscopy, first reported the presence of sible reasons for the development of disease. First de- gadolinium in the affected tissue of 4 of 7 patients with 1 12 13 scribed by Cowper et al in 2000 (using tissue dating from NSF. Days later, Boyd et al confirmed our findings and 1997), NSF was distinguished clinically by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis

High, Whitney A.
JAMA Dermatology , Volume 145 (10) – Oct 1, 2009
Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/estimates-of-risk-empirical-treatment-observations-and-unexpected-Hh8j1erxEe

References (60)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archdermatol.2009.227
pmid
19841408
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis EPHROGENIC SYSTEMIC FIBROSIS (NSF) IS fore the disease developed. In August, Marckmann et al an acquired condition that occurs in the described a series of 13 patients with end-stage renal dis- setting of chronic kidney disease (CKD), ease (7 who were receiving hemodialysis, 1 who was re- and it eventuates as fibrosis of the skin, ceiving peritoneal dialysis, and 5 who did not require di- N soft tissues, and sometimes the viscera. alysis) who developed NSF a mean of 25 days after For nearly a decade, the cause of NSF remained largely gadodiamide exposure. In November, my own research elusive. Only recently have the combined efforts of mul- group, using scanning electron microscopy with energy- tiple investigators shed light on key associations and pos- dispersive spectroscopy, first reported the presence of sible reasons for the development of disease. First de- gadolinium in the affected tissue of 4 of 7 patients with 1 12 13 scribed by Cowper et al in 2000 (using tissue dating from NSF. Days later, Boyd et al confirmed our findings and 1997), NSF was distinguished clinically by

Journal

JAMA Dermatology – American Medical Association

Published: Oct 1, 2009

There are no references for this article.